SELLAS Announces Key Business Objectives for 2025

– Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 – – SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 – – Approval of “tambiciclib” as Recommended International Nonproprietary Name for SLS009 – – Applied for Non-Dilutive Grant Funding to Expand SLS009 Development Into Frontline Setting in AML – – Developing SLS009 Pediatric Programs in Hematological and Potentially Other MalignancieRead More